Biotechnology

Enquiry IconContact Us

The biotech industry includes bio-pharma, bio-services, bio-agri, bio-industrials and bioinformatics. Biopharma is a rapidly growing segment that accounts for a dominant share in this sector. Advancements in biotechnology have enabled researchers to evaluate and identify target biomarkers/cell receptors to develop targeted and personalized therapies. Scientific research and technological advancements have resulted in the emergence of various personalized medicines that are undergoing research. According to research conducted by the Personalized Medicine Coalition, 42% of all compounds and 73% of oncology compounds in the pipeline possess the potential to be personalized medicine. Moreover, according to this study, it is expected that companies will increase their investment in R&D of personalized medicines by 1/3rd over the following five years. The study found that over 20% of drugs approved in 2014 were personalized medicines.

The biotechnology sector has witnessed some disruptive innovations such as gene and cell therapies, immunotherapy, and antibody drug conjugates. Advancement in stem cell therapy is resulting in effective treatment therapies for chronic conditions, organ growth and repair and disease prevention.

Key Challenges

Biotech products have extensive application in oncology and autoimmune disease treatment. However, the cost of these drugs is high owing to extensive research and trials that need to be carried out for the same. Therefore, there is constant pressure to reduce price and increase accessibility, especially in emerging economies. In the U.S., companies are facing reimbursement issues with respect to biopharmaceutical products. Besides, there are regulatory and scientific challenges faced by the sector. Scientific research for new molecules and targeted therapies is capital intensive and challenging owing to growing concern for safety of the drug.

Also, there is lack of awareness about personalized medicine among most healthcare providers, which may hamper its adoption. Clinical adoption of biotechnology products is essential for its success. However, it significant scientific evidence and backing is required to ensure its safety.

“Translating genomic discoveries into personalized medicines entails overcoming substantial scientific, regulatory, and economic challenges, including identifying validated biomarkers, as well as developing personalized therapeutics and clinically relevant diagnostic tests.”

  • Tufts Center for the Study of Drug Development

Opportunities

The biopharmaceutical sector offers vast lucrative growth opportunities. High efficacy and safety of biopharmaceutical products has led to a growth in their demand, Furthermore, consumers are willing to pay high prices for biopharmaceutical products compared to other conventional products. Biopharmaceutical brands have set new standards for blockbuster drugs by recording an annual average sale of over US$ 2bn. Drugs such as Humira have generated sales revenue of over US$ 10bn.

Governments in emerging economies are endorsing biosimilars as cost-effective alternatives to biotech products, which is expected to create significant growth opportunities for manufacturers of generic drugs. Therefore, cost-effectiveness and high quality are prime parameters that need to be considered while developing biosimilars. Recent and upcoming biologic patent expirations include the following:

  • Erbitux (cetuximab) - February 2016
  • Rituxan (rituximab) - September 2016
  • Herceptin (trastuzumab) - June 2019
  • Avastin (bevacizumab) - July 2019
  • Aranesp (darbepoetin alfa) - May 2024
  • Enbrel (etanercept) - November 2028

Companies such as Teva Pharmaceuticals, Hospira, Sandoz, and Amgen are focusing on development of biosimilars and vaccines as preventive measures in addition to treatment. For instance, in 2015, Zarxio TM became the first biosimilar to be approved in the U.S. market. The EMA approved Mosquirix, a malaria vaccine, in the same year. Extensive research is currently underway to develop a dengue vaccine, which could be another breakthrough pharmaceutical product in the near future.

Conclusion

The increasing research in the biotechnology sector is expected to result in higher number of biopharmaceutical products seeking FDA approvals. Biopharmaceuticals are positioned to be promising treatment solutions that would improve patient outcomes and help with reduction of the cost of drug development.

View More

Biotechnology Published Insights

Coherent Market Insights

Monovaccine (Epstein - Barr virus) Market by Application (Mononucleosis, Endemic Burkitt’s lymphoma, Hodgkin’s lymphoma, Gastric carcinomas, Multiple sclerosis, and Nasopharyngeal Carcinoma) and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

Published Date : May 2019

Mononucleosis also known as mono or kissing disease is an infectious illness caused by Epstein-Barr virus. This virus is generally spread through saliva hence, commonly called as kissing disease. It can also be spread through other ways such as sharing drinks or utens... View more

Coherent Market Insights

Influenza Vaccines Market, by Vaccine Type (Trivalent Vaccines and Quadrivalent Vaccines), by Virus Type (Influenza Virus A and Influenza Virus B), by Age Group (Pediatrics and Adults) and by Region - Global Forecast to 2026

Published Date : May 2018

Influenza Vaccines Market Insights – To Stop the Flu Is All Up to You Influenza is a contagious respiratory infection caused due to influenza virus. Influenza is marked by fever, cough, muscles and joi... View more

Coherent Market Insights

Soft Tissue Repair Market, By Product Type (Synthetic, Allograft, Xenograft, Alloplast), By Application (Breast Reconstruction, Hernia, Dermatology, Orthopedics, Dental, Vaginal Sling, Others), By End User (Hospitals, Ambulatory Surgical Centers, Clinics), By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Published Date : Sep 2020

Human body soft tissue comprises tendons, muscles, ligaments, skin, nervous tissue, cartilage, and synovial membrane. Tissue damage causes change in structure and biochemical composition. Soft tissue repair refers to replacement of the destroyed body tissue with livin... View more

Coherent Market Insights

Wound Care Biologics Market - by Product Type (Biologic Skin Substitutes, Enzyme Based Formulations, and Growth Factors), by Application (Chronic Wounds and Acute Wounds), by End User (Hospitals, Clinics, Ambulatory Surgical Centers, and Home Care Settings), and by Region - Global Industry Insights, and Forecast to 2025

Published Date : Apr 2018

Wound Care Biologics Market – Experience the Power of Effective Healing Wound care biologics are bioengineered products used for non-healing wounds of the lower extremity.  Demand for wound care bi... View more

Coherent Market Insights

Stem Cell Banking Market, by Source Type (Cord Blood and Cord Tissue), by Service Type (Collection and Transportation, Processing, Analysis and Storage), by Application (Leukemia, Diabetes, Lymphoma, Cerebral Palsy, Thalassemia and Others), and by Region - Global Trends, and Forecast to 2025

Published Date : Feb 2018

Stem Cell Banking Market – Assurance for a Lifetime Stem cells are building blocks of the immune system and blood, and they have the ability to develop into other cell types, in order to help in repairi... View more

Coherent Market Insights

Genome Engineering Market, By Technology (CRISPR, TALEN, ZFN, and others), By Application (Cell Line Engineering, and Genetic Engineering), By End User (Biotechnology & Pharmaceutical Companies, Research Institutes, and Contract Research Organizations) and by Geography - Global Trends and Forecast to 2025

Published Date : Apr 2018

Genome Engineering Market- Insights Genome engineering is a process of insertion, deletion, modification or replacement of DNA bases in an organism. There are two types of gene therapy, Ex-Vivo Gene Therapy a... View more

Coherent Market Insights

Anti-venom Market, by Anti-venom Type (Polyvalent, Monovalent), by Product Type (Snake Anti-venom, Scorpion Anti-venom, Spider Anti-venom, Other Anti-venom product), by Distribution Channel (Hospitals, Private Clinics, Ambulatory Surgical Centers) - Size, Share, Outlook, and Opportunity Analysis, 2018 – 2026

Published Date : Jan 2019

Anti-venom Market- Insights Anti-venom is a medicine used in the treatment of bite from venomous animals including snake, scorpion, spider, jellyfish, stone fish and others. Anti-venoms are sub-categorized in... View more

Subscribe Newsletter

Kindly subscribe for our latest news & articles.